OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Profiles are based on data from more than 60 million patients, with aim to enable adoption of digital twins and improve patient centricity in drug development.
Phesi, a global provider of patient-centric data software and services, has published the first edition of its Digital Patient Profile (DPP) catalog to deliver granular patient-level data for 28 key disease indications. The profiles, based on 485,000 curated clinical trials and amendments, and data from more than 60 million patients, provide a statistical view of patient attributes for 11 oncology indications and other prevalent diseases including Alzheimer’s, COVID-19, Crohn’s disease and ulcerative colitis. The profiles will be used by sponsors to improve program and trial protocol design, and enable the industry to develop Digital Twins and Digital Trial Arms as part of clinical development strategies. DPPs will also support wider adoption of single arm trials by helping sponsors demonstrate efficacy and safety in relevant patient cohorts.
Dr. Gen Li, Founder and President, Phesi, said in a press release, “What we know about the global patient population has evolved significantly as medicine has advanced, along with other socioeconomic changes. Sponsors must use the data gathered from historical and existing trials and clinical research to move from “perception led” to “data led” program and study design.”
Reference: Phesi publishes first edition of Digital Patient Profile Catalog to enable adoption of Digital Twins and improve patient centricity in drug development. Boston, USA, May 3, 2023.